Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.
You may also be interested in...
Human resource managers also worried that since universal teleworking was valued by employees, a return to pre-pandemic conditions could cause a mass exodus.
Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.